🚨Trade Alert 🚨 SPRC

🚨Trade Alert 🚨 SPRC͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ At Under $1, SPRC May Be the Biggest Growing Story Hiding on the NASDAQ! Greetings All, The legal MJ industry is expected to expand exponentially in the coming years and savvy investors are seeking to profit. It was just last October that President Biden announced MJ reforms which could be the stepping stone for the U.S. to decriminalize the plant on a federal level. In the meantime, as more states in the U.S. and countries decriminalize or legalize the plant and/or its components, there is a growing opportunity on Wall Street to enter the space. With that said, put your attention to SciSparc (SPRC) a small-cap NASDAQ biotech company trading under $1 a share and has an incredibly small trading float! SPRC has been climbing the ranks of the pharma industry and is revolutionizing the way the world approaches modern medicine through cannabinoids and psychedelics! This specialty clinical-stage pharmaceutical company is focusing on the development of therapies to treat disorders of the central nervous system. Led by an experienced team of senior executives and scientists, the company’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The stock has been climbing higher since the year started and there could be more upside ahead given the tiny supply of shares available and because the company had several big announcements this month. Shares have been on the rise since SPRC announced last week an [update on its joint venture with MitoCareX Bio.]( The latter has reached its very first milestone of setting up a “cloud-based computing infrastructure” and now SPRC is further investing in the joint venture and increasing its stake in the company. MitoCareX Bio (which focuses on the discovery and development of potential drugs for cancer, rare diseases and other life-threatening conditions) is currently performing virtual screening activities as well as further developing its computationally based drug discovery platform to enable its planned machine learning capabilities. As a result of MitoCareX Bio meeting this milestone, SPRC will invest an additional $400,000 in MitoCareX Bio and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%. Earlier this month SPRC also announced that as part of its ongoing collaboration with [Clearmind Medicine Inc. (Nasdaq: CMND),]( a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, three provisional patent applications were filed by Clearmind with the United States Patent and Trademark Office (“USPTO”). “These new patent applications continue to support our findings of the major role CannAmideTM, our proprietary PEA formulation, plays in SciSparc’s various proprietary combination treatments,” said Oz Adler, Chief Executive Officer of SciSparc. “All our clinical and pre-clinical studies performed to date, in numerous diseases and conditions, indicated CannAmide™ ability to reduce doses while maintaining therapeutic efficacy and while increasing safety. We have great confidence in our collaboration with Clearmind and believe that together we can maximize the therapeutic effect of our products, potentially offering additional solutions for mental health problems with unmet needs that have limited effective solutions, if at all,” continued Mr. Adler. With so many people around the world suffering from conditions that have no known cure, it’s become vital that research and more is done to help these people and the symptoms they endure as a result of these conditions. With strong leadership, exciting joint ventures, as well as a growing $6M+ market cap and a small trading float, SciSparc Ltd. (NASDAQ: SPRC) is an emerging NASDAQ company that looks positioned to shine bright in the market! [( SciSparc Ltd. NASDAQ: SPRC SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SPRC is well aware of the cannabinoid opportunity in the world of pharmaceuticals and the company is dedicated to developing unique cannabinoid technologies for the treatment of central nervous system disorders. The global cannabis pharmaceutical market size is expected to reach [$127.1 billion by 2028!]( Robust IP Portfolio: Repurposing previously approved compounds qualifies SPRC to take advantage of the FDA’s 505 (b)(2) application protocol. This potentially means lower risk, and an expedited development timeline. The result is a robust pipeline of product candidates well positioned to create significant shareholder value into the future. SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system. Currently, the company’s drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain. The company’s research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) andproducts that constitute a new chemical entity (SCI-160) in order to bring different products to market at different timelines and potentially enable them to generate immediate revenues for the company. Drug Candidates: SCI-110—proprietary drug candidate containing Dronabinol (FDA approved synthetic form of THC), with PEA. - Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids and improve the uptake of THC. - Expected benefits are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events. - Being tested for treatment of Tourette Syndrome (“TS”)- phase IIb, and Alzheimer’s Disease and Agitation- phase IIa. - Results from Phase IIa clinical trial in TS, conducted at Yale University, showed average tic reduction of 21% across the entire sample with almost 40% experiencing a greater than 25% reduction in tics. SCI-210—proprietary drug candidate containing CBD and PEA. - Initially being developed under the regulation of the Israeli Medical Cannabis Agency and Ministry of Health. - SciSparc intends to further develop the product for markets outside of Israel. - Being investigated for Autism Spectrum Disorder (in clinical trials) and Status Epilepticus, which is a form of seizures that are severe and sometimes fatal (preclinical trials). SCI-160—proprietary synthetic CB2 receptor agonist created for the treatment of pain and currently in pre-clinical studies. - The CB2 receptor agonist used in this formulation (HU-433) was invented and synthesized by the Chairman of the SciSparc Scientific Advisory Board and is under a patent granted in the U.S. and Europe. Joint Ventures: Joint Venture Agreement with MitoCareX Bio Ltd. Not long ago, SPRC announced completion of its previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, with MitoCareX Bio Ltd., an Israeli corporation. MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. Because of mitochondrial carriers’ significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers! In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter. Details of the JV agreement can be found [HERE.]( Joint Pre-Clinical Trial with Clearmind Medicine Inc. SPRC has revealed positive safety profile results from its joint pre-clinical trial with Clearmind Medicine Inc., (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial tested the proprietary combination of SPRC’s CannAmide™ with Clearmind's psychedelic molecule, MEAI, for alcohol consumption.The results of this ground-breaking research show potential for the first dedicated cocaine addiction treatment! You can read about the trial [HERE.]( Market Opportunities: A CDC study using parent-reported data found that [1 out of every 333 (0.3%) children 3–17 years of age in the United States have received a diagnosis of TS;]( this is about 174,000 children in 2016–2019. This suggests that about half of children with TS may not be diagnosed. A market opportunity is not one to dismiss… The Tourette Syndrome market is[expected to gain growth at a potential rate of 5.5% in the forecast period of 2021 to 2028.]( The rise in research and development activities is the factor responsible for the market growth. The global [Tourette’s syndrome drugs market]( is poised to reach USD 98.77 million by 2023, according to a new report by Technavio, progressing at a CAGR of 5% during the forecast period. ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity. The global autism spectrum disorder treatment market size was valued at USD 1.85 billion in 2021. The market is[projected to grow from USD 1.93 billion in 2022 to USD 3.17 billion by 2029,]( exhibiting a CAGR of 7.4% during the forecast period. According to the Centers for Disease Control and Prevention (CDC), about 1% of the world's population has autism spectrum disorder – [over 75,000,000 people.]( Major Developments: [SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center]( [SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment]( [SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial]( In Summary… While the usage of cannabis has been popular in recent years, it’s only very recently that we are discovering the rare cannabinoid potential. Early studies have shown the exciting efficacy of cannabinoids against a large variety of diseases. For example, preclinical and clinical studies [have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia](. Psychedelics have also become an increasingly popular area for medical research and studies. A report by [Market Digits]( that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020! SPRC is pioneering the way by developing unique cannabinoid technologies for the treatment of central nervous system (CNS) disorders. The company is also combining cannabinoids with already approved treatments. Excitingly the company is pursuing a restructuring plan which involves transferring its pharmaceutical activities to a new wholly-owned subsidiary. There’s a lot going on with this company and at under $1, this could be a pivotal time to have SPRC on your radar! START YOUR RESEARCH! Copyright 2022 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in SPRC. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party Open Market Media, LLC for a 1 Day Marketing Program regarding SPRC with a start date of 2/27/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042